SGLT-2 inhibitors for COVID-19 — A miracle waiting to happen or just another beat around the bush?
In the absence of an effective drug or vaccine against novel severe acute respiratory syndrome corona virus (SARS-Cov-2) till date, “repurposing approach” of old pharmaceuticals has been applied to combat against 2019-coronavirus disease (COVID-19). Hydroxychloroquine, anti-retrovirals, type-1 angiotesin receptor blockers, statin, vitamin D, melatonin etc are being tried with questionable benefits [1]. While there are intens ive debates regarding safety of different classes of antidiabetics at the advent of COVID-19 [2,3], multiple ongoing studies are evaluating the adjuvant role of various antidiaetics like dipeptidyl peptidase-4 (DPP-4) inhibitors [4,5], pioglitazone [6], glucagon-like peptide-1 (GLP-1) agonists [7] i n reducing the severity of COVID-19.
Source: Primary Care Diabetes - Category: Primary Care Authors: Subhankar Chatterjee Tags: Letter to the Editor Source Type: research
More News: Actos | Cholesterol | Coronavirus | COVID-19 | Diabetes | Diabetes Type 1 | Endocrinology | Hydroxychloroquine | Melatonin | Primary Care | Respiratory Medicine | SARS | Statin Therapy | Study | Vaccines | Vitamin D | Vitamins